Lupin is currently trading at Rs 1367.45, down by 26.60 points or 1.91% from its previous closing of Rs. 1394.05 on the BSE.
The scrip opened at Rs. 1400.00 and has touched a high and low of Rs. 1406.85 and Rs. 1322.65 respectively. So far 294361 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1442.30 on 16-Sep-2014 and a 52 week low of Rs. 841.10 on 21-Nov-2013.
Last one week high and low of the scrip stood at Rs. 1400.00 and Rs. 1351.60 respectively. The current market cap of the company is Rs. 61446.85 crore.
The promoters holding in the company stood at 46.69 % while Institutions and Non-Institutions held 42.71 % and 10.60 % respectively.
Lupin has registered 43.20% fall in its net profit at Rs 459.62 crore for second quarter ended September 30, 2014 as compared to Rs 809.12 crore for the same quarter in the previous year. Total income of the company has decreased 7.62% at Rs 2347.83 crore for Q2FY15 as compared Rs 2541.48 crore for the corresponding quarter previous year.
On consolidated basis, the company’s net profit after taxes and minority interest for the quarter under review registered 55.11% growth at Rs 630.04 crore against Rs 406.18 crore in the September quarter of previous fiscal. The company’s total income has increased by 19.44% at Rs 3283.64 crore for the quarter from Rs 2749.23 crore in the similar quarter of previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1872.60 |
| Dr. Reddys Labs. | 1376.30 |
| Cipla | 1453.50 |
| Zydus Lifesciences | 1121.65 |
| Lupin | 2407.45 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: